Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$3.22
-2.1%
$3.24
$3.04
$18.00
$4.35M0.73105,261 shs4,700 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.33
-2.1%
$0.30
$0.16
$0.42
$10.44M0.7522,655 shs25,673 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.70
-3.6%
$6.11
$2.64
$110.75
$2.85M0.6952,106 shs44,154 shs
Trevena, Inc. stock logo
TRVN
Trevena
$1.10
+1.4%
$1.14
$0.95
$7.85
$1.06M0.632,069 shs185 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00%0.00%0.00%0.00%-67.38%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%+8.71%+1.81%+12.33%+51.01%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.00%-19.77%-37.64%-53.64%-97.14%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+6.67%+2.74%-15.00%-83.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
2.0779 of 5 stars
3.55.00.00.00.00.00.6
Trevena, Inc. stock logo
TRVN
Trevena
1.7731 of 5 stars
3.05.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00
N/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
3.00
Buy$60.002,122.22% Upside
Trevena, Inc. stock logo
TRVN
Trevena
2.00
Hold$5.00354.55% Upside

Current Analyst Ratings Breakdown

Latest INBP, GHSI, JAGX, and TRVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
First Berlin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.35$0.14 per share23.15$6.39 per share0.50
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$50.32M0.20$0.04 per share7.61$0.64 per share0.52
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.69M0.24N/AN/A$12.29 per share0.22
Trevena, Inc. stock logo
TRVN
Trevena
$443K2.38N/AN/A($11.07) per share-0.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$4.870.66N/A22.79%-73.69%-48.17%N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$110K$0.048.25N/A2.37%6.36%4.84%N/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)

Latest INBP, GHSI, JAGX, and TRVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million
5/14/2025Q3 2025
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A$0.02N/A$0.02N/A$13.95 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$5.00155.28%N/A102.67%N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
16.68
16.59
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.72
1.70
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
22.20
1.08
0.70
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
1.32%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.20%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.38%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
101.35 million1.33 millionNot Optionable
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15030.98 million10.16 millionNot Optionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
501.02 million1.01 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000Optionable

Recent News About These Companies

JMP Securities downgrades Trevena (TRVN) to a Hold
Lyme Regis town councillor John Trevena stand down
Trevena appoints new financial chief
Trevena Appoints Katrine Sutton as New CFO
Learn to Evaluate (TRVN) using the Charts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Guardion Health Sciences stock logo

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.33 -0.01 (-2.08%)
As of 02:51 PM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$2.70 -0.10 (-3.57%)
Closing price 04:00 PM Eastern
Extended Trading
$2.68 -0.02 (-0.74%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Trevena stock logo

Trevena NASDAQ:TRVN

$1.10 +0.02 (+1.38%)
As of 09:54 AM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.